Prospective Randomized Comparative Study of the Treatment of Multisegmental Fibrostenosing Crohn's Disease.

计划入组 120 人 · 首次发布于 2021 年 4 月 29 日

NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease

计划入组 320 人 · 首次发布于 2026 年 7 月 6 日

A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease

计划入组 6 人 · 首次发布于 2026 年 2 月 23 日

Crohn's disease(Tscan)

Crohn's Disease(Akthelia)

Crohn's disease therapeutic

Rare Disease Research, LLC

CASTLEMAN DISEASE COLLABORATIVE NETWORK

United States

CURE RARE DISEASE, INC.

United States

Agomab's AGMB-129 Shows Promising Results in Phase 2a Trial for Fibrostenosing Crohn's Disease

Agomab's Ontunisertib Achieves Primary Safety Endpoint in First-in-Class Phase 2a Trial for Fibrostenosing Crohn's Disease

Agomab Unveils Design for First-Ever Phase 2b Trial in Fibrostenosing Crohn's Disease with Oral ALK5 Inhibitor Ontunisertib